Martin Chandler

Q: What is Martin Chandler email address?

Email Martin Chandler at mchandler@werewolftx.com. This email is the most updated Martin Chandler email found in 2026.

Q: How to contact Martin Chandler?

To contact Martin Chandler send an email to mchandler@werewolftx.com. If you want to call Martin Chandler try calling on +13867344228.

Senior Director of Process Development and Manufacturing at Werewolf Therapeutics | Santa Clara, California, United States

About Martin Chandler

Martin Chandler serves as the Senior Director of Process Development and Manufacturing at Werewolf Therapeutics, where he plays a pivotal role in advancing the company's innovative immuno-oncology programs. With over 25 years of extensive experience in protein purification, Martin specializes in developing downstream processes for a diverse range of biologics, including mammalian cell, yeast, and microbial-derived products. His expertise encompasses a variety of purification techniques, such as chromatography, filtration, and centrifugation, which are critical for the successful development of conditionally active cytokine therapeutics derived from the PREDATOR™ platform.

In his current role, Martin leads the process development and manufacturing efforts for INDUKINE™ molecules, ensuring that these novel therapeutics meet stringent regulatory standards while maintaining high efficiency and yield. He oversees the activities of Contract Research Organizations (CROs) and Contract Development and Manufacturing Organizations (CDMOs), managing complex CMC budgets and contributing to the Chemistry, Manufacturing, and Controls (CMC) sections of Investigational New Drug (IND) filings. His proficiency in high-throughput screening using TECAN systems and BioMEK automation enhances the scalability and reproducibility of biotherapeutic processes, allowing for rapid advancements in vaccine and biopharmaceutical development.

Martin's commitment to cGMP manufacturing practices ensures that all processes adhere to the highest quality standards, positioning Werewolf Therapeutics at the forefront of biotherapeutic innovation. His comprehensive knowledge of tangential flow filtration and yeast recombinant protein purification further solidifies his role as a leader in the field, driving the development of next-generation therapies that have the potential to transform patient outcomes in immuno-oncology.

Martin Chandler Work